MX2021004907A - Vacuna de ibv 4/91 con proteina espicular heterologa. - Google Patents

Vacuna de ibv 4/91 con proteina espicular heterologa.

Info

Publication number
MX2021004907A
MX2021004907A MX2021004907A MX2021004907A MX2021004907A MX 2021004907 A MX2021004907 A MX 2021004907A MX 2021004907 A MX2021004907 A MX 2021004907A MX 2021004907 A MX2021004907 A MX 2021004907A MX 2021004907 A MX2021004907 A MX 2021004907A
Authority
MX
Mexico
Prior art keywords
present
ibv
subject
relates
heterologous
Prior art date
Application number
MX2021004907A
Other languages
English (en)
Inventor
Annika Kraemer-Kuehl
Hans-Christian Philipp
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of MX2021004907A publication Critical patent/MX2021004907A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Entre otros asuntos, la presente invención se refiere a un IBV (virus de la bronquitis infecciosa) 4/91 que codifica una proteína S (espicular) heteróloga o fragmento de esta. Además, la presente invención se refiere a una composición inmunógena que comprende dicho IBV 4/91 que codifica una proteína S (espicular) heteróloga o fragmento de esta. Asimismo, la presente invención se refiere a métodos para inmunizar un sujeto, que comprenden administrar a dicho sujeto la composición inmunógena de la presente invención. Además, la presente invención se refiere a métodos para tratar o prevenir signos clínicos causados por un IBV en un sujeto que lo necesita, en donde el método comprende administrar al sujeto una cantidad terapéuticamente eficaz de una composición inmunógena de acuerdo con la presente invención.
MX2021004907A 2018-10-31 2019-10-28 Vacuna de ibv 4/91 con proteina espicular heterologa. MX2021004907A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18203626 2018-10-31
PCT/EP2019/079389 WO2020089164A1 (en) 2018-10-31 2019-10-28 4/91 ibv vaccine with heterologous spike protein

Publications (1)

Publication Number Publication Date
MX2021004907A true MX2021004907A (es) 2021-06-15

Family

ID=64048879

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004907A MX2021004907A (es) 2018-10-31 2019-10-28 Vacuna de ibv 4/91 con proteina espicular heterologa.

Country Status (12)

Country Link
US (2) US11224649B2 (es)
EP (1) EP3873516A1 (es)
JP (1) JP7206383B2 (es)
KR (1) KR20210087058A (es)
CN (1) CN112996537A (es)
AR (1) AR116876A1 (es)
BR (1) BR112021008440A2 (es)
CO (1) CO2021005066A2 (es)
EA (1) EA202191145A1 (es)
IL (1) IL282465A (es)
MX (1) MX2021004907A (es)
WO (1) WO2020089164A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021022651A2 (pt) 2019-05-10 2021-12-28 Boehringer Ingelheim Vetmedica Gmbh Subunidade s1 modificada da proteína spike de coronavírus
AU2021378483A1 (en) * 2020-11-12 2023-06-08 Intervet International B.V. Recombinant vectors encoding chimeric coronavirus spike proteins and use thereof
CN117737298B (zh) * 2023-09-22 2024-06-25 江苏农牧科技职业学院 同时鉴别不同基因型禽传染性支气管炎病毒的多重pcr引物、检测试剂、方法及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
DE69426051T2 (de) * 1993-07-30 2001-05-10 Akzo Nobel Nv Impfstoff für Geflügel
JP2003503039A (ja) * 1999-06-25 2003-01-28 マキシジェン， インコーポレイテッド 弱毒化したワクチンの操作のための方法および組成物
DE60141743D1 (de) 2000-02-29 2010-05-20 Wyeth Llc In ovo schutz gegen infektiöse bronchitis
ES2333223T3 (es) 2003-03-03 2010-02-18 Intervet International B.V. Virus de la bronquitis infecciosa que contiene un gen punta modificado.
ZA200603404B (en) * 2003-10-30 2007-09-26 Boehringer Ingelheim Vetmed Erysipelothrix rhusiopathiae-haemophilus parasuis vaccine and methods of using the same
US8679504B2 (en) * 2008-05-22 2014-03-25 University Of Georgia Research Foundation Inc. Poultry viral materials and methods related thereto
AR072976A1 (es) * 2008-08-08 2010-10-06 Wyeth Corp Virus de bronquitis infecciosa (ib) aislado, composicion de vacuna y metodo para preparar un virus de bronquitis infecciosa (ib) atenuado vivo
GB0911794D0 (en) * 2009-07-07 2009-08-19 Animal Health Inst Chimaeric protein
US20140141043A1 (en) * 2012-11-16 2014-05-22 Auburn University Compositions, vectors, kits, and methods for immunizing against avian infectious bronchitis virus
WO2016064841A1 (en) * 2014-10-20 2016-04-28 Auburn University Adaptation of attenuated infectious bronchitis virus (ibv) to embryonic kidney cells and vaccine thereby produced
EP3261664A1 (en) * 2015-02-26 2018-01-03 Boehringer Ingelheim Vetmedica GmbH Bivalent swine influenza virus vaccine
EA201990010A1 (ru) * 2016-06-16 2019-07-31 Бёрингер Ингельхайм Ветмедика Гмбх Вакцина против вируса инфекционного бронхита
US20190358316A1 (en) * 2017-02-06 2019-11-28 University Of Maryland, College Park Infectious bronchitis virus vaccine using newcastle disease viral vector
US10772953B2 (en) * 2017-08-09 2020-09-15 Auburn University Recombinant spike ectodomain proteins, compositions, vectors, kits, and methods for immunizing against avian infectious bronchitis virus

Also Published As

Publication number Publication date
KR20210087058A (ko) 2021-07-09
JP7206383B2 (ja) 2023-01-17
CN112996537A (zh) 2021-06-18
EP3873516A1 (en) 2021-09-08
AR116876A1 (es) 2021-06-23
US11224649B2 (en) 2022-01-18
BR112021008440A2 (pt) 2021-09-28
CO2021005066A2 (es) 2021-04-30
WO2020089164A1 (en) 2020-05-07
US11744888B2 (en) 2023-09-05
US20220265815A1 (en) 2022-08-25
IL282465A (en) 2021-06-30
US20200129613A1 (en) 2020-04-30
EA202191145A1 (ru) 2021-08-23
JP2022512836A (ja) 2022-02-07

Similar Documents

Publication Publication Date Title
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
MX2021004907A (es) Vacuna de ibv 4/91 con proteina espicular heterologa.
MX2018015506A (es) Vacuna contra virus de bronquitis infecciosa.
PH12019500592A1 (en) New swine influenza vaccine
PH12019500954A1 (en) Vaccine against porcine parvovirus
BR112018012962A2 (pt) vacinas de zika recombinantes
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
MX2022010588A (es) Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2.
BRPI1007721B1 (pt) composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66
RU2014127714A (ru) ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
UA114286C2 (uk) Спосіб лікування staphylococcus aureus
MX2022014387A (es) Vacunas contra coronavirus a base de vaccinia ankara sintetica modificada (smva).
NZ721015A (en) Mutant fragments of ospa and methods and uses relating thereto
MX2019014184A (es) Virus oncoliticos y metodo.
MX2021004859A (es) Vacuna de ibv h52 con proteina espicular heterologa.
PH12020500194A1 (en) Malaria vaccine
AU2018347511A8 (en) Periodontitis vaccine and related compositions and method of use
MX2022006414A (es) Vacuna triple contra avibacterium paragallinarum y el virus de la encefalomielitis aviar y el virus de la viruela aviar.
MX2022009549A (es) Tratamiento que implica vacunacion con antigeno y agentes de union que se unen a pd-l1 y cd137.
MX2022001742A (es) Metodos para prevenir el dengue y la hepatitis a.
BR112022009507A2 (pt) Uma nova vacina contra heamophilus parasuis
EA201270794A1 (ru) Маркерная вакцина против классической чумы свиней
WO2023031306A3 (en) New coronavirus vaccine and method for designing and obtaining a virus vaccine
RU2020118606A (ru) Вакцина против кошачьего калицивируса
WO2023066229A3 (en) Recombinant classical swine fever virus e2 protein with b/c domain swapping